Stem Cell Therapy for MS Shows Promise More By Dennis ThompsonHealthDay Reporter HealthDay MONDAY, Dec. 29, 2014 (HealthDay News) -- An experimental therapy that kills off and then "resets" the immune system has given three years of remission to a small group of multiple sclerosis patients,...
After six and 12 months, however, the researchers found no differences in disability between patients who underwent stem cell therapy and controls, or individuals with MS who received another treatment or a placebo. Moreover, the use of the stem cell therapies did not signif...
For patients with multiple sclerosis (MS), current treatment options only address early-stage symptoms of the debilitating disease. Now, new research has found a potential treatment that could both stop disease progression and repair existing damage.Nicole Kwan...
The researchers hope that a cell transplant shortly after the injury will limit that over-response while still promoting anti-inflammatory healing. The Houston trial has enrolled about 14 of the 55 patients it needs for its adult trial and about 38 of 50 patients for a pediatric trial. (You ...
Shoddy stem cell preparation may have led to some of the patients' complications, which could have been caused by injection of a contaminant or the cell wash solution into the eye, Albini said. When injected into the eye, the stem cells also could have changed into myofibroblasts, a type of...
Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MS
Better pre-transplant treatment options forTP53-mutated MDS: cytoreductive or non-cytoreductive therapy? Bingqian Jiang Tingting Yang Jimin Shi Research04 Dec 2024Bone Marrow Transplantation P: 1-9 High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vit...
and insulin doses will be measured during the study. The primary endpoint will be the change of dosage of the insulin of the treated T1DM patients within a 3-month time frame. Additionally, β-cell mass and HbA1c levels will be measured at the end of the study and compared to the basel...
disease severity: patients with accumulating disability who still retain the ability to walk are most likely to benefit from aHSCT.Is HSC therapy for MS safe?Early transplant-related complications, like fever, diarrhea, and low blood cell counts, are common after the aHSCT procedure.More...
we noted an association between higher stem cell doses and a reduction in brain volume. Similar effects have been seen with potentdrugs used for patients with early MS, suggesting a possible role of the cells in preventing brain inflammation and swelling. ...